HC Wainwright Has Negative Outlook for SLNO Q1 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Analysts at HC Wainwright reduced their Q1 2025 earnings estimates for shares of Soleno Therapeutics in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.83) per share for the quarter, down from their prior estimate of ($0.71). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.84) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.34) EPS.

Several other equities research analysts have also recently weighed in on the company. Stifel Nicolaus initiated coverage on Soleno Therapeutics in a research note on Wednesday. They set a “buy” rating and a $74.00 target price for the company. Lifesci Capital upgraded shares of Soleno Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 4th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $72.00 price objective on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $71.20.

Soleno Therapeutics Stock Performance

Shares of Soleno Therapeutics stock opened at $44.99 on Thursday. The stock has a market cap of $1.94 billion, a PE ratio of -13.55 and a beta of -1.46. The firm has a 50-day moving average of $47.20 and a 200-day moving average of $49.86. Soleno Therapeutics has a 52-week low of $36.61 and a 52-week high of $60.92.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41).

Insider Activity at Soleno Therapeutics

In other Soleno Therapeutics news, CFO James H. Mackaness sold 4,083 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total value of $185,409.03. Following the completion of the transaction, the chief financial officer now owns 115,089 shares in the company, valued at $5,226,191.49. This represents a 3.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bhatnagar Anish sold 10,937 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $496,649.17. Following the completion of the transaction, the chief executive officer now owns 708,616 shares in the company, valued at approximately $32,178,252.56. The trade was a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 17,360 shares of company stock valued at $790,119 over the last 90 days. Insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On Soleno Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Harbor Capital Advisors Inc. purchased a new stake in shares of Soleno Therapeutics during the 3rd quarter valued at $1,820,000. Victory Capital Management Inc. raised its position in Soleno Therapeutics by 25.9% during the third quarter. Victory Capital Management Inc. now owns 13,509 shares of the company’s stock valued at $682,000 after purchasing an additional 2,782 shares in the last quarter. Curi RMB Capital LLC bought a new stake in Soleno Therapeutics during the third quarter worth about $202,000. Intech Investment Management LLC purchased a new position in shares of Soleno Therapeutics in the 3rd quarter worth about $262,000. Finally, HealthInvest Partners AB bought a new position in shares of Soleno Therapeutics during the 3rd quarter valued at about $1,332,000. 97.42% of the stock is currently owned by institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.